243 related articles for article (PubMed ID: 25124473)
1. FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer.
Jin Y; Han B; Chen J; Wiedemeyer R; Orsulic S; Bose S; Zhang X; Karlan BY; Giuliano AE; Cui Y; Cui X
Ann Surg Oncol; 2014 Dec; 21 Suppl 4(0 4):S758-66. PubMed ID: 25124473
[TBL] [Abstract][Full Text] [Related]
2. Identification of EGF-NF-κB-FOXC1 signaling axis in basal-like breast cancer.
Chung S; Jin Y; Han B; Qu Y; Gao B; Giuliano AE; Cui X
Cell Commun Signal; 2017 Jun; 15(1):22. PubMed ID: 28629477
[TBL] [Abstract][Full Text] [Related]
3. FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signaling.
Wang J; Ray PS; Sim MS; Zhou XZ; Lu KP; Lee AV; Lin X; Bagaria SP; Giuliano AE; Cui X
Oncogene; 2012 Nov; 31(45):4798-802. PubMed ID: 22249250
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis of Basal-Like Breast Cancer Using a FOXC1-Based Assay.
Jensen TW; Ray T; Wang J; Li X; Naritoku WY; Han B; Bellafiore F; Bagaria SP; Qu A; Cui X; Taylor CR; Ray PS
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26041837
[TBL] [Abstract][Full Text] [Related]
6. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
[TBL] [Abstract][Full Text] [Related]
7. The role and the potential regulatory pathways of high expression of forkhead box C1 in promoting tumor growth and metastasis of basal-like breast cancer.
Zuo HD; Wu Yao W
J BUON; 2016; 21(4):818-825. PubMed ID: 27685901
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of FOXC1 as a therapeutic target for basal-like breast cancer.
Mott L; Su K; Pack DW
Cancer Gene Ther; 2018 May; 25(3-4):84-91. PubMed ID: 29511313
[TBL] [Abstract][Full Text] [Related]
9. The potential pathway of FOXC1 high expression in regulating the proliferation, migration, cell cycle and epithelialmesenchymal transition of basal-like breast cancer and in vivo imaging.
Zuo H; Yang Q
J BUON; 2018; 23(3):720-728. PubMed ID: 30003742
[TBL] [Abstract][Full Text] [Related]
10. Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study.
Ray PS; Bagaria SP; Wang J; Shamonki JM; Ye X; Sim MS; Steen S; Qu Y; Cui X; Giuliano AE
Ann Surg Oncol; 2011 Dec; 18(13):3839-47. PubMed ID: 21424368
[TBL] [Abstract][Full Text] [Related]
11. FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer.
Wang J; Xu Y; Li L; Wang L; Yao R; Sun Q; Du G
Cancer Med; 2017 Jan; 6(1):275-287. PubMed ID: 28028927
[TBL] [Abstract][Full Text] [Related]
12. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.
Du J; Li L; Ou Z; Kong C; Zhang Y; Dong Z; Zhu S; Jiang H; Shao Z; Huang B; Lu J
Breast Cancer Res Treat; 2012 Jan; 131(1):65-73. PubMed ID: 21465172
[TBL] [Abstract][Full Text] [Related]
13. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer.
Ray PS; Wang J; Qu Y; Sim MS; Shamonki J; Bagaria SP; Ye X; Liu B; Elashoff D; Hoon DS; Walter MA; Martens JW; Richardson AL; Giuliano AE; Cui X
Cancer Res; 2010 May; 70(10):3870-6. PubMed ID: 20406990
[TBL] [Abstract][Full Text] [Related]
14. Forkhead box C1 boosts triple-negative breast cancer metastasis through activating the transcription of chemokine receptor-4.
Pan H; Peng Z; Lin J; Ren X; Zhang G; Cui Y
Cancer Sci; 2018 Dec; 109(12):3794-3804. PubMed ID: 30290049
[TBL] [Abstract][Full Text] [Related]
15. FOXC1 identifies basal-like breast cancer in a hereditary breast cancer cohort.
Johnson J; Choi M; Dadmanesh F; Han B; Qu Y; Yu-Rice Y; Zhang X; Bagaria S; Taylor C; Giuliano AE; Amersi F; Cui X
Oncotarget; 2016 Nov; 7(46):75729-75738. PubMed ID: 27708239
[TBL] [Abstract][Full Text] [Related]
16. EBP50 inhibits EGF-induced breast cancer cell proliferation by blocking EGFR phosphorylation.
Yao W; Feng D; Bian W; Yang L; Li Y; Yang Z; Xiong Y; Zheng J; Zhai R; He J
Amino Acids; 2012 Nov; 43(5):2027-35. PubMed ID: 22476347
[TBL] [Abstract][Full Text] [Related]
17. Forkhead box C1 promoter upstream transcript, a novel long non-coding RNA, regulates proliferation and migration in basal-like breast cancer.
Liu J; Shen L; Yao J; Li Y; Wang Y; Chen H; Geng P
Mol Med Rep; 2015 Apr; 11(4):3155-9. PubMed ID: 25516208
[TBL] [Abstract][Full Text] [Related]
18. KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene.
Roberts MS; Anstine LJ; Finke VS; Bryson BL; Webb BM; Weber-Bonk KL; Seachrist DD; Majmudar PR; Keri RA
Breast Cancer Res; 2020 Jun; 22(1):66. PubMed ID: 32552913
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of EGF/EGFR activation with naphtho[1,2-b]furan-4,5-dione blocks migration and invasion of MDA-MB-231 cells.
Hsieh CY; Tsai PC; Tseng CH; Chen YL; Chang LS; Lin SR
Toxicol In Vitro; 2013 Feb; 27(1):1-10. PubMed ID: 23064031
[TBL] [Abstract][Full Text] [Related]
20. COUP-TFII Knock-down Promotes Proliferation and Invasion in Colorectal Cancer Cells
Yun SH; Han SH; Park JI
Anticancer Res; 2020 Jan; 40(1):177-190. PubMed ID: 31892566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
